Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

NCT02973789 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

291

Enrollment

INDUSTRY

Sponsor class

Conditions

Nonsmall Cell Lung Cancer
NSCLC

Interventions

DEVICE: NovoTTF-200T
DRUG: Immune checkpoint inhibitors or docetaxel

Sponsor

NovoCure GmbH